Placeholder

The C-Suite: Corporate Strategies

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

Product Description

According to a recent Quintiles New Health report, a lack of capital and the increased reluctance of payers to reimburse for new medications are serious concerns among biopharma companies.

Everyone is in agreement that the current level of healthcare spending is unsustainable, and one of the chief culprits is the industry’s current business model, says Colin Hill, CEO, president, chairman, and co-founder of GNS Healthcare.

Sidebar:
Trending Now…
Hot Button Issues in Biotechnology
Outcomes: The New Reality

FEEDBACK